Sandbox ID Gastrointestinal and Intraabdominal: Difference between revisions

Jump to navigation Jump to search
Line 161: Line 161:


===Peptic ulcer disease===
===Peptic ulcer disease===
*Preferred regimen: The current treatment of choice for H. pylori infected patients is a combination of PPI (standard dose twice daily) with [[Amoxicillin]] (1 g twice daily) and [[Clarithromycin]] (500 mg twice daily) administered for 7-10 days (7-day therapy is approved with [[Rabeprazole]]; 10-day therapy is approved with [[Lansoprazole]], [[Omeprazole]], [[Pantoprazole]], and [[Esomeprazole]]). [[Metronidazole]] (400 mg twice daily) may be substituted for [[Amoxicillin]] in this regimen if the patient is allergic to Penicillin.
*Alternative regimen: An alternative strategy is the combination of [[Bismuth]], [[Metronidazole]], and [[Tetracycline]] (Bismuth subsalicylate 525 mg QID + [[Metronidazole]] 250 mg QID + [[Tetracycline]] 500 mg QID) combined with a PPI for 14 days.


===Peritonitis, secondary to bowel  perforation===
===Peritonitis, secondary to bowel  perforation===

Revision as of 18:05, 3 June 2015

Anthrax, gastrointestinal

  • Gastrointestinal anthrax [1]
  • Preferred regimen: Ciprofloxacin 400 mg intravenously every 8 h OR Doxycycline 100 mg intravenously every 12 h combined with second agent: Clindamycin 600 mg intravenously every 8 h or Penicillin G 4 MU every 4-6 hours OR Meropenem 1 gm intravenously every 6-8 hours or Rifampin 300 mg every 12 h.
  • Note:Treatment for 60 days is recommended to avoid relapse or breakthrough of incubating disease. If initial therapy is intravenous, then convert to oral administration (Ciprofloxacin or Doxycycline) when clinically indicated. Steroids may be considered as an adjunct therapy for patients with severe edema and for meningitis. For pregnant women, avoid Doxycycline. Use Ciprofloxacin and switch to oral penicillin once susceptibilities are known.

Appendicitis

Biliary sepsis

Cholangitis

Cholecystitis

Diverticulitis

Esophagitis

Hepatic abscess

Hepatitis A

Hepatitis B

Hepatitis C

Hepatitis D

Hepatitis E

Infectious diarrhea

Immunocompetent

  • Shigella species
  • Preferred regimen:
  • Preferred regimen:
  • Non-typhi species of Salmonella
  • Preferred regimen: Not recommended routinely, but if severe or patient is <6 monthes or >50 year old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, TMP-SMZ (if susceptible) OR Fluoroquinolone, bid for 5 to 7 days; Ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses
  • Campylobacter species
  • Escherichia coli species
  • Enterotoxigenic
  • Enteropathogenic
  • Enteroinvasive
  • Enterohemorrhagic
  • Preferred regimen: Avoid antimotility drugs; role of antibiotics unclear, and administration should be avoided.
  • Aeromonas/Plesiomonas
  • Yersinia species
  • Vibrio cholerae O1 or O139
  • Toxigenic Clostridium difficile
  • Preferred regimen: Offending antibiotic should be withdrawn if possible; Metronidazole, 250 mg qid to 500 mg tid for 3 to 10 days
  • Giardia
  • Cryptosporidium species
  • Preferred regimen: If severe, consider Paromomycin, 500 mg tid for 7 days
  • Isospora species
  • Preferred regimen: TMP-SMZ, 160 and 800 mg, respectively, bid for 7 to 10 days
  • Cyclospora species
  • Preferred regimen: TMP/SMZ, 160 and 800 mg, respectively, bid for 7 days
  • Microsporidium species
  • Preferred regimen: Not determined
  • Entamoeba histolytica

Immunocompromised

  • Shigella species:
  • Preferred regimen:
  • Preferred regimen:
  • Non-typhi species of Salmonella
  • Preferred regimen: Not recommended routinely, but if severe or patient is <6 monthes or >50 year old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, TMP-SMZ (if susceptible) OR Fluoroquinolone, bid for 14 days (or longer if relapsing); ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses
  • Campylobacter species
  • Preferred regimen:Erythromycin, 500 mg bid for 5 days (may require prolonged treatment)
  • Escherichia coli species
  • Enterotoxigenic
  • Enteropathogenic
  • Enteroinvasive
  • Enterohemorrhagic
  • Preferred regimen: Avoid antimotility drugs; role of antibiotics unclear, and administration should be avoided.
  • Aeromonas/Plesiomonas
  • Yersinia species
  • Vibrio cholerae O1 or O139
  • Toxigenic Clostridium difficile
  • Preferred regimen: Offending antibiotic should be withdrawn if possible; Metronidazole, 250 mg qid to 500 mg tid for 3 to 10 days
  • Giardia
  • Cryptosporidium species
  • Preferred regimen: Paromomycin, 500 mg tid for 14 to 28 days, then bid if needed; highly active antiretroviral therapy including a protease inhibitor is warranted for patients with AIDS
  • Isospora species
  • Preferred regimen: TMP-SMZ, 160 and 800 mg, respectively, qid for 10 days, followed by TMP-SMZ thrice weekly, or weekly Sulfadoxine (500 mg) and Pyrimethamine (25 mg) indefinitely for patients with AIDS
  • Cyclospora species
  • Preferred regimen: TMP-SMZ, 160 and 800 mg, respectively, qid for 10 days, followed by TMP-SMZ thrice weekly indefinitely
  • Microsporidium species
  • Preferred regimen: Albendazole, 400 mg bid for 3 weeks; highly active antiretroviral therapy including a protease inhibitor is warranted for patients with AIDS
  • Entamoeba histolytica

Leptospirosis

Pancreatitis

Peliosis hepatitis

Peptic ulcer disease

Peritonitis, secondary to bowel perforation

Peritonitis, secondary to dialysis

Peritonitis, secondary to ruptured appendix

Peritonitis, secondary to ruptured diverticula

Peritonitis, spontaneous bacterial

Post-transplant infected biloma

Splenic abscess

Tropical sprue

Typhlitis

Variceal bleeding, prophylaxis

Whipple's disease

References

  1. Sweeney DA, Hicks CW, Cui X, Li Y, Eichacker PQ (2011). "Anthrax infection". Am J Respir Crit Care Med. 184 (12): 1333–41. doi:10.1164/rccm.201102-0209CI. PMC 3361358. PMID 21852539.
  2. 2.0 2.1 2.2 2.3 Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV; et al. (2001). "Practice guidelines for the management of infectious diarrhea". Clin Infect Dis. 32 (3): 331–51. doi:10.1086/318514. PMID 11170940.